A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
allow for the importation of affordable and safe drugs 
by wholesale distributors, pharmacies, and individuals. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Affordable and Safe 
4
Prescription Drug Importation Act’’. 
5
03:51 May 27, 2021
H2181
2 
•HR 2181 IH
SEC. 2. IMPORTING AFFORDABLE AND SAFE DRUGS. 
1
(a) IN GENERAL.—Section 804 of the Federal Food, 
2
Drug, and Cosmetic Act (21 U.S.C. 384) is amended to 
3
read as follows: 
4
‘‘SEC. 804. IMPORTATION OF SAFE AND AFFORDABLE 
5
DRUGS 
BY 
WHOLESALE 
DISTRIBUTORS, 
6
PHARMACIES, AND INDIVIDUALS. 
7
‘‘(a) IN GENERAL.—Not later than 180 days after 
8
the date of enactment of the Affordable and Safe Prescrip-
9
tion Drug Importation Act, the Secretary shall promulgate 
10
regulations permitting the importation of qualifying pre-
11
scription drugs into the United States, in accordance with 
12
this section. 
13
‘‘(b) DEFINITIONS.—For purposes of this section: 
14
‘‘(1) CERTIFIED FOREIGN SELLER.—The term 
15
‘certified foreign seller’ means a licensed foreign 
16
pharmacy or foreign wholesale distributor that the 
17
Secretary certifies under subsection (d)(1)(B), that 
18
pays the fee required under subsection (d)(1)(C), 
19
and that is included on the list described in sub-
20
section (c). 
21
‘‘(2) FOREIGN
WHOLESALE
DISTRIBUTOR.— 
22
The term ‘foreign wholesale distributor’ means a 
23
person (other than a manufacturer, a manufactur-
24
er’s co-licensed partner, a third-party logistics pro-
25
03:51 May 27, 2021
H2181
3 
•HR 2181 IH
vider, or a repackager) engaged in wholesale dis-
1
tribution. 
2
‘‘(3) IMPORTER.—The term ‘importer’ means a 
3
dispenser (as defined in section 581(3)) or wholesale 
4
distributor registered under section 503(e) who im-
5
ports prescription drugs into the United States in 
6
accordance with this section. 
7
‘‘(4) LICENSED
FOREIGN
PHARMACY.—The 
8
term ‘licensed foreign pharmacy’ means a pharmacy 
9
located in Canada, or subject to subsection (e), an-
10
other applicable country, that— 
11
‘‘(A) operates in accordance with applica-
12
ble pharmacy standards set forth by the provin-
13
cial pharmacy rules and regulations enacted in 
14
Canada, or, subject to subsection (e), such ap-
15
plicable rules and regulations of the permitted 
16
country in which such seller is located; and 
17
‘‘(B) is licensed to operate and dispense 
18
prescription drugs to individuals in Canada, or, 
19
subject to subsection (e), the permitted country 
20
in which the pharmacy is located. 
21
‘‘(5) QUALIFYING
PRESCRIPTION
DRUG.—The 
22
term ‘qualifying prescription drug’— 
23
‘‘(A) means a prescription drug that— 
24
03:51 May 27, 2021
H2181
4 
•HR 2181 IH
‘‘(i) is approved for use in patients, 
1
and marketed, in Canada, or subject to 
2
subsection (e), approved for use in pa-
3
tients, and marketed, in another permitted 
4
country; 
5
‘‘(ii) is manufactured in a facility reg-
6
istered under subsection (b)(1) or (i) of 
7
section 510 that is in compliance with good 
8
manufacturing practices regulations of the 
9
Food and Drug Administration; 
10
‘‘(iii) has the same active ingredient 
11
or ingredients, route of administration, and 
12
strength as a prescription drug approved 
13
under chapter V, or, for purposes of sub-
14
paragraph (B)(iv), is biosimilar to an ap-
15
proved biological product and has the same 
16
route of administration and strength as the 
17
approved biological product; and 
18
‘‘(iv) is labeled in accordance with— 
19
‘‘(I) the laws of Canada, or an-
20
other country from which importation 
21
is permitted pursuant to subsection 
22
(e); and 
23
03:51 May 27, 2021
H2181
5 
•HR 2181 IH
‘‘(II) the requirements promul-
1
gated by the Secretary, which shall in-
2
clude labeling in English; 
3
‘‘(B) with respect to importers only, in-
4
cludes— 
5
‘‘(i) peritoneal dialysis solution; 
6
‘‘(ii) insulin; 
7
‘‘(iii) a drug for which a risk evalua-
8
tion and mitigation strategy is required 
9
under section 505–1; 
10
‘‘(iv) biological products, as defined in 
11
section 351 of the Public Health Service 
12
Act that are proteins (except any chemi-
13
cally synthesized polypeptides) or analo-
14
gous products; and 
15
‘‘(v) intravenously infused drugs; and 
16
‘‘(C) does not include— 
17
‘‘(i) a controlled substance (as defined 
18
in section 102 of the Controlled Sub-
19
stances Act); 
20
‘‘(ii) an anesthetic drug inhaled dur-
21
ing surgery; or 
22
‘‘(iii) a compounded drug. 
23
‘‘(6) VALID
PRESCRIPTION.—The term ‘valid 
24
prescription’ means a prescription that is issued for 
25
03:51 May 27, 2021
H2181
6 
•HR 2181 IH
a legitimate medical purpose in the usual course of 
1
professional practice by— 
2
‘‘(A) a practitioner who has conducted at 
3
least one in-person medical evaluation of the 
4
patient; or 
5
‘‘(B) a covering practitioner. 
6
‘‘(c) PUBLICATION OF CERTIFIED FOREIGN SELL-
7
ERS.—The Secretary shall publish on a dedicated internet 
8
website a list of certified foreign sellers, including the 
9
internet website address, physical address, and telephone 
10
number of each such certified foreign seller. 
11
‘‘(d) ADDITIONAL CRITERIA.— 
12
‘‘(1) CERTIFIED FOREIGN SELLERS.— 
13
‘‘(A) IN GENERAL.—To be a certified for-
14
eign seller, such seller shall— 
15
‘‘(i) be certified by the Secretary in 
16
accordance with subparagraph (B); 
17
‘‘(ii) pay the registration fee estab-
18
lished under subparagraph (C); and 
19
‘‘(iii) sell only qualifying prescription 
20
drugs to importers or individuals who im-
21
port prescription drugs into the United 
22
States in accordance with this section. 
23
03:51 May 27, 2021
H2181
7 
•HR 2181 IH
‘‘(B) CERTIFICATION.—To be a certified 
1
foreign seller, the Secretary shall certify that 
2
such seller— 
3
‘‘(i) is a foreign wholesale distributor 
4
or licensed foreign pharmacy operating an 
5
establishment, which may include an online 
6
foreign pharmacy, that is located in Can-
7
ada, or, subject to subsection (e), another 
8
permitted country; 
9
‘‘(ii) is engaged in the distribution or 
10
dispensing of a prescription drug that is 
11
imported or offered for importation into 
12
the United States; 
13
‘‘(iii) has been in existence for a pe-
14
riod of at least 5 years preceding the date 
15
of such certification and has a purpose 
16
other than to participate in the program 
17
established under this section; 
18
‘‘(iv) in the case of a certified foreign 
19
seller that is a licensed foreign pharmacy, 
20
agrees to dispense a qualifying prescription 
21
drug to an individual in the United States 
22
only after receiving a valid prescription, as 
23
described in paragraph (2)(C); 
24
03:51 May 27, 2021
H2181
8 
•HR 2181 IH
‘‘(v) has processes established by the 
1
seller, or participates in another estab-
2
lished process, to certify that the physical 
3
premises and data reporting procedures 
4
and licenses are in compliance with all ap-
5
plicable laws and regulations of Canada, 
6
or, subject to subsection (e), the permitted 
7
country in which the seller is located, and 
8
has implemented policies designed to mon-
9
itor ongoing compliance with such laws 
10
and regulations; 
11
‘‘(vi) conducts or commits to partici-
12
pate in ongoing and comprehensive quality 
13
assurance programs and implements such 
14
quality 
assurance 
measures, 
including 
15
blind testing, to ensure the veracity and re-
16
liability of the findings of the quality as-
17
surance program; 
18
‘‘(vii) agrees that, pursuant to sub-
19
section (g), laboratories approved by the 
20
Secretary may be authorized to conduct 
21
product testing to determine the chemical 
22
authenticity 
of 
sample 
pharmaceutical 
23
products; 
24
03:51 May 27, 2021
H2181
9 
•HR 2181 IH
‘‘(viii) agrees to notify the Secretary, 
1
importers, and individuals of product re-
2
calls in Canada, or pursuant to subsection 
3
(e), the permitted country in which the 
4
seller is located, and agrees to cease, or re-
5
frain from, exporting such product; 
6
‘‘(ix) has established, or will establish 
7
or participate in, a process for resolving 
8
grievances, as defined by the Secretary, 
9
and will be held accountable for violations 
10
of established guidelines and rules; 
11
‘‘(x) except as otherwise permitted 
12
under this section, does not sell products 
13
that the seller could not otherwise legally 
14
sell in Canada, or, subject to subsection 
15
(e), the permitted country in which such 
16
seller is located to customers in the United 
17
States; and 
18
‘‘(xi) meets any other criteria estab-
19
lished by the Secretary. 
20
‘‘(C) CERTIFICATION FEE.—Not later than 
21
30 days before the start of each fiscal year, the 
22
Secretary shall establish a fee to be collected 
23
from foreign sellers for such fiscal year that are 
24
certified under subparagraph (B), in an amount 
25
03:51 May 27, 2021
H2181
10 
•HR 2181 IH
that is sufficient, and not more than necessary, 
1
to pay the costs of administering the program 
2
under this section, and enforcing this section 
3
pursuant to section 303(h), for that fiscal year. 
4
‘‘(D) RECERTIFICATION.—A certification 
5
under subparagraph (B) shall be in effect for a 
6
period of 2 years, or until there is a material 
7
change in the circumstances under which the 
8
foreign seller meets the requirements under 
9
such subparagraph, whichever occurs earlier. A 
10
foreign seller may reapply for certification 
11
under such subparagraph (B), in accordance 
12
with a process established by the Secretary. 
13
‘‘(2) INDIVIDUALS.—An individual may import 
14
a qualifying prescription drug described in sub-
15
section (b) from Canada or another country pursu-
16
ant to subsection (e) if such drug— 
17
‘‘(A) is dispensed, including through an 
18
online pharmacy, by a certified foreign seller 
19
that is a licensed foreign pharmacy; 
20
‘‘(B) is purchased for personal use by the 
21
individual, not for resale, in quantities that do 
22
not exceed a 90-day supply; and 
23
‘‘(C) is filled only after providing to the li-
24
censed foreign pharmacy a valid prescription 
25
03:51 May 27, 2021
H2181
11 
•HR 2181 IH
issued by a health care practitioner licensed to 
1
practice in a State in the United States. 
2
‘‘(e) IMPORTATION FROM OTHER COUNTRIES.—Be-
3
ginning on the date that is 2 years after the date on which 
4
final regulations are promulgated to carry out this section, 
5
if, based on a review of the evidence obtained after such 
6
effective date, including the reports submitted under sec-
7
tion 2(d) of the Affordable and Safe Prescription Drug 
8
Importation Act, that importation of qualifying prescrip-
9
tion drugs from Canada under this section resulted in cost 
10
savings for consumers in the United States and increased 
11
access to safe medication, the Secretary shall have the au-
12
thority to permit importation of qualifying prescription 
13
drugs by importers and individuals from, in addition to 
14
Canada, any country that— 
15
‘‘(1) is a member of the Organisation for Eco-
16
nomic Co-operation and Development; and 
17
‘‘(2) has statutory or regulatory standards for 
18
the approval and sale of prescription drugs that are 
19
comparable to the standards in the United States 
20
and that— 
21
‘‘(A) authorizes the approval of drugs only 
22
if a drug has been determined to be safe and 
23
effective by experts employed by or acting on 
24
behalf of a governmental entity and qualified by 
25
03:51 May 27, 2021
H2181
12 
•HR 2181 IH
scientific training and experience to evaluate 
1
the safety and effectiveness of drugs; 
2
‘‘(B) requires that any determination of 
3
safety and effectiveness described in subpara-
4
graph (A) be made on the basis of adequate 
5
and well-controlled investigations, including 
6
clinical investigations, as appropriate, con-
7
ducted by experts qualified by scientific training 
8
and experience to evaluate the safety and effec-
9
tiveness of drugs; 
10
‘‘(C) requires the methods used in, and the 
11
facilities and controls used for, the manufac-
12
ture, processing, and packing of drugs in the 
13
country to be adequate to preserve the identity, 
14
quality, purity, and strength of the drugs; and 
15
‘‘(D) requires the reporting of adverse re-
16
actions to drugs and establish procedures to re-
17
call, and withdraw approval of, drugs found not 
18
to be safe or effective. 
19
‘‘(f) LABELING.—Any qualifying prescription drug 
20
imported that meets the labeling requirements described 
21
in subsection (b)(5)(A)(iv) is deemed not misbranded for 
22
purposes of section 502. 
23
‘‘(g) DRUG
TESTING
LABORATORIES.—The Sec-
24
retary may approve one or more laboratories to conduct 
25
03:51 May 27, 2021
H2181
13 
•HR 2181 IH
random testing of prescription drugs sold by certified for-
1
eign sellers to assess the chemical authenticity of such 
2
drugs. 
3
‘‘(h) UNFAIR AND DISCRIMINATORY ACTS AND PRAC-
4
TICES.—It is unlawful for a manufacturer, directly or indi-
5
rectly (including by being a party to a licensing agreement 
6
or other agreement)— 
7
‘‘(1) to discriminate by charging a higher price 
8
for a prescription drug sold to a certified foreign 
9
seller that sells such drug to an importer in accord-
10
ance with this section than the price that is charged, 
11
inclusive of rebates or other incentives to the coun-
12
try from which the drug is exported, to another per-
13
son that is in the same country and that does not 
14
import such a drug into the United States in accord-
15
ance with this section; 
16
‘‘(2) except with respect to a prescription drug 
17
on the drug shortage list under section 506E, dis-
18
criminate by denying, restricting, or delaying sup-
19
plies of a prescription drug to a certified foreign sell-
20
er, on account of such seller’s status as a certified 
21
foreign seller, that sells such drug to an importer in 
22
accordance with this section, or by publicly, pri-
23
vately, or otherwise refusing to do business with 
24
03:51 May 27, 2021
H2181
14 
•HR 2181 IH
such a certified foreign seller on account of such 
1
seller’s status as a certified foreign seller; 
2
‘‘(3) cause there to be a difference (including a 
3
difference in active ingredient, route of administra-
4
tion, bioequivalence, strength, formulation, manufac-
5
turing establishment, manufacturing process, or per-
6
son that manufactures the drug) between a prescrip-
7
tion drug for distribution in the United States and 
8
the drug for distribution in Canada or another per-
9
mitted country, subject to subsection (e), for the 
10
purpose of avoiding sales by certified foreign sellers; 
11
or 
12
‘‘(4) except with respect to a prescription drug 
13
on the drug shortage list under section 506E, en-
14
gage in any other action to restrict, prohibit, or 
15
delay the importation of a prescription drug under 
16
this section. 
17
‘‘(i) INFORMATION AND RECORDS.— 
18
‘‘(1) BIANNUAL REPORTS.—Each importer shall 
19
submit biannual reports to the Secretary which shall 
20
contain, for each qualifying prescription drug im-
21
ported into the United States— 
22
‘‘(A) the unique facility identifier of the 
23
manufacturer of the drug, described in section 
24
510; 
25
03:51 May 27, 2021
H2181
15 
•HR 2181 IH
‘‘(B) the transaction information described 
1
in section 581(26) (other than the information 
2
described in subparagraph (C)); and 
3
‘‘(C) the price paid by the importer for the 
4
drug. 
5
‘‘(2) MAINTENANCE
OF
RECORDS
BY
SEC-
6
RETARY.—The Secretary shall maintain information 
7
and documentation submitted under paragraph (1) 
8
for such period of time as the Secretary determines 
9
to be appropriate. 
10
‘‘(j) SUSPENSION OF IMPORTATION.— 
11
‘‘(1) PATTERNS
OF
NONCOMPLIANCE.—The 
12
Secretary shall require that importation of a specific 
13
qualifying prescription drug or importation by a spe-
14
cific certified foreign seller or importer pursuant to 
15
this section be immediately suspended if the Sec-
16
retary determines that there is a pattern of importa-
17
tion of such specific drug or by such specific seller 
18
or importer that involves counterfeit drugs, drugs 
19
that have been recalled or withdrawn, or drugs in 
20
violation of any requirement of this section, until an 
21
investigation is completed and the Secretary deter-
22
mines that importation of such drug or by such sell-
23
er or importer does not endanger the public health. 
24
03:51 May 27, 2021
H2181
16 
•HR 2181 IH
‘‘(2) TEMPORARY SUSPENSION.—The Secretary 
1
may require that importation of a specific qualifying 
2
prescription drug or importation by a specific cer-
3
tified foreign seller or importer pursuant to this sec-
4
tion be temporarily suspended if, with respect to 
5
such drug, seller, or importer, there is a violation of 
6
any requirement of this section or if the Secretary 
7
determines that importation of such drug or by such 
8
seller or importer might endanger the public health. 
9
Such temporary suspension shall apply until the Sec-
10
retary completes an investigation and determines 
11
that importation of such drug or by such seller or 
12
importer does not endanger the public health. 
13
‘‘(k) SUPPLY CHAIN SECURITY.— 
14
‘‘(1) PURCHASE FROM REGISTERED FACILITIES 
15
AND CERTIFIED FOREIGN SELLERS.— 
16
‘‘(A) IN GENERAL.—Except as provided in 
17
subparagraph (B), certified foreign sellers who 
18
sell qualifying prescription drugs for importa-
19
tion into the United States pursuant to this 
20
section may purchase such drugs only from 
21
manufacturers or entities registered under sec-
22
tion 510 or other certified foreign sellers. 
23
‘‘(B) EXCEPTION.—Certified foreign sellers 
24
who sell qualifying prescription drugs for im-
25
03:51 May 27, 2021
H2181
17 
•HR 2181 IH
portation into the United States pursuant to 
1
this section may purchase such drugs from for-
2
eign sellers in Canada or another permitted 
3
country, even if such foreign seller is not a 
4
manufacturer registered under section 510 or a 
5
certified foreign seller, if the Secretary enters 
6
into a memorandum of understanding or coop-
7
erative agreement with Canada, or such other 
8
permitted country, to ensure compliance, to the 
9
extent appropriate and feasible, with subchapter 
10
H of chapter V. The Secretary shall seek to 
11
enter into such a memorandum of under-
12
standing or cooperative agreement with Canada 
13
and each country from which importation is 
14
permitted under subsection (e). 
15
‘‘(2) IMPORTATION TRACING.—Certified foreign 
16
sellers shall provide importers with the unique facil-
17
ity identifier associated with the manufacturer reg-
18
istered under section 510 of the qualifying prescrip-
19
tion drug and the information under paragraph 
20
(25), paragraph (26) (other than subparagraph (C)), 
21
and subparagraphs (D), (F), and (G) of paragraph 
22
(27) of section 581. Certified foreign sellers shall 
23
provide such information to individuals purchasing 
24
such drugs, upon request. 
25
03:51 May 27, 2021
H2181
18 
•HR 2181 IH
‘‘(l) REMS.—In the case of an importer that imports 
1
a qualifying prescription drug, where the drug with the 
2
same active ingredient or ingredients (or that is biosimilar 
3
to an approved biological product), route of administra-
4
tion, and strength that is approved under chapter V or 
5
section 351 of the Public Health Service Act is subject 
6
to elements to assure safe use under section 505–1, such 
7
importer shall be subject to such elements to assure safe 
8
use, as applicable and appropriate. 
9
‘‘(m) CONSTRUCTION.—Nothing in this section limits 
10
the authority of the Secretary relating to the importation 
11
of prescription drugs, other than with respect to section 
12
801(d)(1) as provided in this section.’’. 
13
(b) PENALTIES WITH RESPECT TO ONLINE PHAR-
14
MACIES.—Section 303 of the Federal Food, Drug, and 
15
Cosmetic Act (21 U.S.C. 333) is amended by adding at 
16
the end the following: 
17
‘‘(h) In the case of person operating an internet 
18
website, whether in the United States or in another coun-
19
try, that violates section 301(aa) by— 
20
‘‘(1) selling, by means of the internet, with the 
21
intent to defraud or mislead or with reckless dis-
22
regard for safety of the public, an adulterated or 
23
counterfeit drug to an individual in the United 
24
States; or 
25
03:51 May 27, 2021
H2181
19 
•HR 2181 IH
‘‘(2) dispenses, by means of the internet, a drug 
1
to an individual in the United States who the person 
2
knows or has reasonable cause to believe, does not 
3
possess a valid prescription for that drug, 
4
such person shall be imprisoned for not more than 10 
5
years or fined not more than $250,000.’’. 
6
(c) NO PREEMPTION.—Nothing in this Act, including 
7
the amendments made by this Act, shall be construed to 
8
preempt, alter, displace, abridge, or supplant any remedy 
9
available under any State or Federal law, including com-
10
mon law, that provides a remedy for civil relief. 
11
(d) REPORTS.— 
12
(1) HHS.—Not later than 1 year after the date 
13
on which final regulations are promulgated to carry 
14
out section 804 of the Federal Food, Drug, and Cos-
15
metic Act (21 U.S.C. 384), as amended by this Act, 
16
and every 2 years thereafter, the Secretary of 
17
Health and Human Services, after consultation with 
18
appropriate Federal agencies, shall submit to Con-
19
gress and make public a report on the importation 
20
of drugs into the United States. 
21
(2) GAO REPORT.—Not later than 18 months 
22
after the date on which final regulations are promul-
23
gated to carry out section 804 of the Federal Food, 
24
Drug, and Cosmetic Act (21 U.S.C. 384), as amend-
25
03:51 May 27, 2021
H2181
20 
•HR 2181 IH
ed by this Act, the Comptroller General of the 
1
United States shall submit to Congress a report con-
2
taining an analysis of the implementation of the 
3
amendments made by this Act, including a review of 
4
drug safety and cost-savings and expenses, including 
5
cost-savings to consumers in the United States and 
6
trans-shipment and importation tracing processes, 
7
resulting from such implementation. 
8
Æ 
03:51 May 27, 2021
H2181
